Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-15T23:20:13.949Z Has data issue: false hasContentIssue false

Changes in intravenous and oral antimicrobial prescriptions during the coronavirus disease 2019 (COVID-19) pandemic: an experience at a tertiary-care center

Published online by Cambridge University Press:  05 April 2022

Shutaro Murakami
Affiliation:
Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, JapanDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Kiyose, Japan
Akane Takamatsu
Affiliation:
Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Manabu Akazawa
Affiliation:
Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Kiyose, Japan
Takao Goto
Affiliation:
Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Toshiki Miwa
Affiliation:
Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Yoshiyasu Terayama
Affiliation:
Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Hitoshi Honda*
Affiliation:
Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
*
Author for correspondence: Hitoshi Honda MD, Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-8524, Japan. E-mail: hhhhonda@gmail.com

Abstract

Antimicrobial use during the coronavirus disease 2019 (COVID-19) pandemic at a tertiary-care center was analyzed using interrupted time-series analysis. Among intravenous antimicrobials, the use of azithromycin and third-generation cephalosporins significantly decreased during the current pandemic. Similarly, the use of oral antimicrobials, including azithromycin and fluoroquinolones, also decreased.

Information

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and/or adaptation of the article.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Fig. 1.Changes in intravenous (inpatient) and oral (outpatient) antimicrobial use during the prepandemic and pandemic periods. Intravenous antimicrobials (overall, third-generation cephalosporins, and azithromycin) and oral antimicrobials (overall, fluoroquinolones, and azithromycin). Note. DOT, days of therapy.

Figure 1

Table 1.Changes in Intravenous and Oral Antimicrobial Use During the Study Period Using Interrupted Time-Series Analysis